Heptares and AstraZeneca enter agreement to develop treatments for a range of cancers
Advertisement
Heptares Therapeutics announced that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Under the terms of the agreement, Heptares will grant AstraZeneca an exclusive license to research, develop, manufacture and commercialise HTL-1071. The companies will also collaborate to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.
Heptares will receive an upfront payment of $10 million and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events. Subject to successful completion of development and commercialisation milestones, Heptares is also eligible to receive more than $500 million, as well as up to double-digit tiered royalties on net sales.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Cells as computers - Such reprogrammed cells could perform medical tasks in our bodies, such as diagnosing diseases or providing treatment
17 Million for Future Cancer Diagnoses
BioVaria Startup Awards go to OPSYON and LIfT Biosciences - 11th BioVaria Sees Record Attendance
Phylogica licenses technology to Janssen Biotech, Inc.
Biotools, B & M Labs, S.A. - Madrid, Spain
Structure of key complex in the immune system - New study reveals the structure of complement component C1 – a target for complement-mediated diseases including strokes and heart attacks
Computer tool analyzes in detail genetic alterations in the genome of cancer cells - Developed by CSIC, CiberAMP allows establishing direct correlations between changes in the number of gene copies in tumor cells and their expression levels
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to address Huntington’s disease
Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform